Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.11
+0.06 (0.43%)
Jul 6, 2026, 1:20 PM EDT - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 161 employees as of December 31, 2025. The number of employees decreased by 139 or -46.33% compared to the previous year.
Employees
161
Change (1Y)
-139
Growth (1Y)
-46.33%
Revenue / Employee
$193
Profits / Employee
-$1,530,472
Market Cap
329.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 161 | -139 | -46.33% | 161 | 0 |
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 161 |
| Zentalis Pharmaceuticals | 106 |
| Foghorn Therapeutics | 106 |
| Lineage Cell Therapeutics | 77 |
| Larimar Therapeutics | 71 |
| InflaRx | 65 |
| Immuneering | 55 |
| Inhibikase Therapeutics | 35 |
LYEL News
- 4 hours ago - AbCellera apponts Lynn Seely to board of directors - TheFly
- 6 days ago - Lyell Immunopharma Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 11 days ago - Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 24 days ago - Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress - GlobeNewsWire
- 26 days ago - Lyell Immunopharma Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Lyell Immunopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Lyell Immunopharma provides update on safety profile of LYL273 - TheFly
- 4 weeks ago - Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion - GlobeNewsWire